XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue Recognition (Tables)
6 Months Ended
Jun. 30, 2023
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue The following table represents Evolent’s revenue disaggregated by end-market and product type:
For the Three Months Ended June 30,For the Six Months Ended June 30,
2023202220232022
Medicaid$209,318 $141,502 $392,352 $279,303 
Medicare138,700 111,392 266,369 208,492 
Commercial and other121,118 67,045 238,105 129,201 
Total$469,136 $319,939 $896,826 $616,996 
Performance Suite$276,576 $208,085 $516,449 $379,249 
Specialty Technology and Services Suite77,052 12,874 142,368 26,454 
Administrative Services77,754 92,357 160,821 199,216 
Cases37,754 6,623 77,188 12,077 
Total$469,136 $319,939 $896,826 $616,996 
Schedule of Contract with Customer, Asset and Liability
The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of June 30, 2023 and December 31, 2022 (in thousands):
June 30, 2023December 31, 2022
Short-term receivables (1)
$344,781 $246,209 
Short-term deferred revenue6,950 5,758 
Long-term deferred revenue1,853 2,533 
————————
(1)Excludes pharmacy claims receivable and premiums receivable.
Changes in deferred revenue for the six months ended June 30, 2023, are as follows (in thousands):
Deferred revenue
Balance as of beginning-of-period$8,291 
Reclassification to revenue, as a result of performance obligations satisfied(4,722)
Cash received in advance of satisfaction of performance obligations5,234 
Balance as of end of period$8,803